Objective: To examine the effect of low-dose ®sh oil supplementation on speci®c growth factors, purported to play a central role in lesion formation, and also on the total growth factor activity of serum, as assessed by the induction of DNA synthesis in cultured human arterial smooth muscle cells. Design: Randomized placebo-controlled double-blind intervention study. Setting: Free-living population. Subjects: Sixty-three healthy volunteers, 37 males and 26 females. Interventions: Four treatment regimes with subjects receiving 0, 0.3,0.6 or 0.9 gaday of n-3 PUFA for an 8 week period. Blood samples were taken at baseline and following the 8 week intervention. All samples were analysed in batch following completion of the study. Results: Consumption of ®sh oil had no effect on serum platelet-derived growth factor (PDGF), or transforming growth factor beta (TGFb) concentration. Furthermore, ®sh oil supplementation did not alter the total growth factor activity of serum. Conclusions: Results indicate that low-dose ®sh oil supplementation, equivalent to about two portions of fatty ®sh per week and providing less than 1 g n-3 PUFAaday, does not alter the levels of the major serum growth factors and does not modify total serum growth factor activity in healthy human volunteers. Sponsorship: European Union shared cost project (FAIR-CT-95-0085).
Introduction
Platelets and smooth muscle cells are involved, under pathological conditions, in the progression of atherosclerosis (Ross, 1979) in ischaemic heart disease (IHD). Con-sequently, research has centred on the possibility of modulating these cells in order to reduce the development of atherosclerotic plaques. In addition to their role in primary lesion formation, smooth muscle cells and platelets are also, at least partly, responsible for the problem of restenosis following angioplasty (MacLeod et al, 1994; Markovitz et al, 1996) and its resultant clinical complications. A number of studies have reported that growth factors, released by vascular and circulatory cells at the site of the endothelial damage, mediate the proliferation of vascular smooth muscle cells. Platelet-derived growth factor (PDGF) expression is elevated in human atherosclerotic plaques compared with normal arteries, and increased plasma concentrations of PDGF have been reported in patients with diagnosed vascular disease (Wallace et al, 1998; Nilsson et al, 1986) . Total mitogenic activity of serum for smooth muscle cells is elevated in individuals at risk of developing the clinical symptoms of IHD (Koschinsky et al, 1987) and also in acute studies of patients undergoing coronary angioplasty (Caplice et al, 1997) .
Epidemiological evidence suggests that coronary events are less frequent in populations with a high ®sh intake (Bang & Dyerberg, 1972) , while clinical studies report a reduction in all-cause mortality among MI patients who consume ®sh regularly (Burr et al., 1989; GISSI-Prevenzione Investigators, 1999) . The bene®cial effects of ®sh oil have been attributed to their long-chain n-3 polyunsaturated fatty acid (PUFA) content. The exact mechanisms by which n-3 PUFAs exert their bene®cial effects, however, remains to be elucidated. Fish oil has been reported to favourably modulate lipoprotein metabolism (Connor et al, 1993) , haemostatic factors (Archer et al, 1998) , and blood pressure (Morris et al, 1993) . Dietary n-3 fatty acids have also been reported to reduce mechanically induced lesion formation in animal models (Zhu et al, 1988) , an observation which may be, at least partially, explained by the effect of ®sh oil on growth factor levels. Dietary n-3 polyunsaturated fatty acids (PUFA), given at moderately high doses (3.7 ± 7 g n-3 PUFAaday), have been reported to modulate the expression of speci®c cytokines and growth factors (Endres et al, 1989; Caughey et al, 1996; Baumann et al, 1999) , and to alter total serum growth factor activity (Mata et al, 1997) . In the present study we have investigated whether lowdose ®sh oil supplementation (providing 0.9 g n-3 PUFAa day and equivalent to two portions of fatty ®sh per week) alters the serum concentrations of speci®c growth factors thought to play a central role in lesion formation. We also evaluated the effect of serum obtained from the subjects on arterial smooth muscle cell DNA synthesis by S-phase incorporation of 3 H-thymidine.
Materials and methods
Subject selection and study design Sixty-three healthy volunteers, 37 males and 26 females, were recruited to participate in the intervention study. The average age of the volunteers was 32.7 (s.d. 9.73) y (range 19 ± 50 y), while the average body mass index (BMI) of the study group was 24.4 (s.d. 2.6) kgam 2 (range 20.3 ± 31.1). The volunteers were all non-smokers, with a habitually low intake of ®sh and no previous history of hyerlipidaemia or endocrine disease. None of the volunteers was adhering to any form of special diet or taking dietary fatty acid supplements. Informed consent was obtained from each subject at the time of recruitment to the study, which was approved by the Ethics Committee of the Federated Dublin Voluntary Hospitals in Ireland. The subjects were requested not to change their habitual diets during the intervention period.
The study was a randomized placebo-controlled doubleblind study. Subjects were allocated to one of four intervention groups receiving 0, 0.3, 0.6 or 0.9 g n-3 PUFA per day for 8 weeks. Olive oil was used as the placebo, and the two intermediate doses of n-3 PUFA were composed of a blend of olive oil and ®sh oil to ensure that all subjects received an equal energy intake from the supplements. Table 1 shows the EPA and DHA composition of the supplements. Each supplement contained equal quantities of a-tocopherol (1134 mgakg), b-tocopherol (8 mgakg) and g-tocopherol (20 mgakg). Subjects consumed three 1 g capsules per day for the 8 week intervention period.
Blood sampling
Venous blood samples were taken, following an overnight fast (12 h), at baseline and again after the 8 week intervention period. All samples were kept refrigerated until centrifugation and all samples were stored at À70 C until required for batch analysis at the end of the study.
Determination of PDGF and TGFb
Serum concentration of PDGF was measured using a commercially available human PDGF-AB immunoassay (R&D Systems, Abingdon, UK). This assay employs a quantitative`sandwich' enzyme immunoassay technique using a microtitre plate coated with PDGF-AA antibody along with a secondary antibody for PDGF-BB. The method, therefore, measures only PDGF-AB. The detection limit of the assay was 84 pgaml and the interassay coef®-cient of variation was 5.8%. Serum TGFb was measured using the Human TGFb ELISA system, DuoSeT (Genzyme Diagnostics). The detection limit of the assay was 62.5 pgaml and the interassay coef®cient of variation was 6.4%.
Assessment of growth factor activity of human serum using a DNA synthesis assay Human umbilical arterial smooth muscle cells (HUASMC), isolated from umbilical arteries by the explant technique and presented as a 10-donor pool preparation, were obtained (Technoclone, Germany). The cells were maintained in M199 with Earles salts (Gibco Life Technologies Ltd, Paisley, Scotland) supplemented with 20% FBS (Gibco), 1% penicillinastreptomycin (Gibco) and 50 mgaml endothelial cell growth supplement (ECGS) (Sigma-Aldrich, Poole, England) and passaged every 3 ± 4 days by trypsinization. Cells were used for experiments between passages three and eight.
Cells were trypsinized, resuspended in growth medium and an aliquot placed in 24-well plates. The plates were incubated at 37 C and the cells grown to subcon¯uency (72 h approximately). The medium was replaced with serum-free medium and the plates incubated for a further 48 h to render the cells quiescent in the G 0 aearly G 1 phase. Serum (15% of ®nal well volume) from the study subjects was incubated with the synchronized HUAMCs. Serum from each subject taken at the two time points was assayed in parallel. An aliquot of pooled human serum was run on each plate as a control. The plates were incubated for 24 h. Labelled thymidine incorporation to newly formed DNA was used as an index of cell proliferation. Following the 24 h incubation, cells were pulsed with [6-3H]-TdR (Amersham International, Buckinghamshire, UK), 0.5 mCiawell for 6 h. Cells were washed with ice-cold phosphate buffered saline (PBS), ®xed with methanol, treated with trichloracetic acid at 4 C and solubilized with 0.5 mmolal NaOHa0.5% SDS. The solubilized samples were transferred to scintillation vials and counted for radioactivity using a scintillation counter (Wallac, Pharmacia LKB). Results are expressed as stimulation index, which is the counts per minute normalized by counts per minute from control wells containing arrested G 0 cells.
Assessment of platelet fatty acid composition
Platelet-rich plasma was prepared by centrifugation at 140 g. The platelet-rich fraction was then centrifuged at 670 g and the platelet pellet washed and resuspended in Tris:EDTA buffer. Lipids were extracted using a chloroform methanol extraction and the phospholipid fraction isolated as described previously (Roche and Gibney, 1994) . Platelet phospholipid fatty acid methyl esters were generated by esteri®cation using boron tri¯uoride methanol and identi®ed by gas liquid chromatography as described previously (Roche and Gibney, 1994) .
Statistical analysis
Results are expressed as mean + s.e.m. Analysis of covariance (ANCOVA) using week 0 value as a covariate was used to test for an effect of treatment. Statistical analysis was performed using SPSS for Windows. 
Results
There was no signi®cant difference between the four intervention groups with respect to sex, age or BMI ( Table 2 ). The dietary interventions were isocaloric and BMI was not altered by the dietary intervention. Haematological parameters assessed at baseline and following the 8 week intervention period were within the normal ranges and did not change over the intervention period (results not shown).
Compliance with the intervention regimen was assessed by analysis of fatty acids in the platelet fraction. Levels of the n-3 PUFA, EPA, increased in a dose-dependent manner over the 8 week intervention (Table 3 ), indicating that compliance among the subjects was excellent.
There was no signi®cant difference among the four groups at baseline in serum PDGF and TGFb concentration (Table 4 ). There was no signi®cant effect of 8 weeks supplementation on the serum levels of PDGF or on the serum levels of TGFb (Table 4) . Human umbilical arterial smooth muscle cell premitotic DNA synthesis, following the addition of baseline and week 8 serum samples, was not altered signi®cantly by ®sh oil supplementation at a dose of up to 0.9 g of n-3 PUFA per day (Table 4) .
Discussion
In the current study, we demonstrate that supplementing the diet of apparently healthy volunteers with low doses of ®sh oil, equivalent to two portions of oily ®sh per week, does not alter the serum concentration of PDGF, TGFb or the total growth factor activity of the serum for arterial smooth muscle cells. It appears, therefore, that previous reported effects of higher levels of n-3 PUFA supplementation on growth factors (Baumann et al, 1999 ) and on growth factor Table 4 The effect of n-3 PUFA supplementation on serum platelet-derived growth factor (PDGF) and transforming growth factor beta (TGFb) concentration and serum growth factor activity (SI) for smooth muscle cells. Analysis of covariance showed no signi®cant effect of treatment on serum PDGF and TGFb concentration and on serum SI for smooth muscle cells Table 3 The effect of n-3 PUFA supplementation on platelet phospholipid fatty acid pro®le (mmol % of total). Analysis of covariance revealed a signi®cant effect of treatment on platelet phospholipid EPA (P 0.001) Low-dose ®sh oil supplementation JMW Wallace et al activity (Mata et al, 1997) may not be evident with these low doses of n-3 PUFA supplementation which are readily achievable by increasing dietary fatty ®sh intakes. Previously it has been reported that short-term ®sh oil supplementation, with the supplements administered at a moderately high level, 7 g ®sh oiladay containing 65% long chain n-3 PUFA, reduced the expression of PDGF-A and PDGF-B in both stimulated and unstimulated mononuclear cells (Baumann et al, 1999) . Furthermore, we have previously reported that short-term low-dose ®sh oil supplementation reduced the concentration of PDGF in plasma of healthy women (Wallace et al, 1995) . The results from the current study, therefore, appear to contradict our previous ®ndings. This may be due to two notable differences between the two studies. Firstly, the duration of supplementation varied between the two studies; the initial intervention was only for 4 weeks, while the current study lasted 8 weeks. To date, all studies reporting a modulating effect of ®sh oil on PDGF have been 4 week interventions Wallace et al, 1995; Baumann et al, 1999) . Based on the results of the current study, it appears that the effects on growth factors observed with short-term supplementation may not persist over a longer term intervention period. Given that individuals consuming either oily ®sh or ®sh oil are likely to do so habitually, longer term studies will be required in order to fully elucidate the role of n-3 PUFA in modulating growth factors. Furthermore, it would be of interest to compare the effect of ®sh oil supplementation on growth factors after 4 and 8 weeks supplementation in such intervention studies. The other major difference between the current study and our previous study was that in the earlier study, plasma levels of PDGF were assessed, providing a measure of the circulating levels of PDGF. In contrast, in the current study, serum PDGF was assessed. Serum PDGF is a measure of circulating PDGF and PDGF released from the platelet fraction upon activation. It is possible, given the welldocumented effect of ®sh oil reducing platelet activity (Munehira et al, 1999) , that, under normal physiological conditions, ®sh oil supplementation could inhibit the release of PDGF from the a-granules in platelets, and thereby the circulating levels of PDGF, without in¯uencing the total PDGF content of the granules. Therefore, plasma levels of PDGF would fall following ®sh oil supplementation without a concomitant fall in serum PDGF levels. Fish oil-enriched diets have previously been reported to reduce tissue TGFb mRNA expression in speci®c animal models of disease (Chandrasekar et al, 1995) . However, our ®nding of no effect of n-3 fatty acid supplementation on TGFb is in keeping with an earlier study which reported that dietary n-3 fatty acids did not alter TGFb mRNA expression in mononuclear cells .
PDGF and TGFb modulate the proliferation of smooth muscle cells in vitro and studies have reported alterations in these growth factors in IHD (Wallace et al, 1998; Borkowski et al, 1995) . PDGF is the major mitogen for smooth muscle cells, while in contrast, TGFb inhibits the proliferation of vascular smooth muscle cells (Reddy and Howe, 1993) , An alteration in the serum level of growth factors could have a signi®cant effect on serum growth factor activity for smooth muscle cells. The current investigation reported no effect on low-dose ®sh oil supplementation on serum growth factor activity as assessed by premitotic DNA synthesis in smooth muscle cells. This, perhaps, was not surprising, given our ®nding that the serum concentration of PDGF and TGFb were not altered by ®sh oil supplementation. However, this ®nding is in contrast to a previous study which reported that serum, obtained from individuals who were consuming a diet providing 3.8 g n-3 PUFAaday, induced greater premitotic DNA synthesis than when the same individuals were fed a saturated, monounsaturated or n-6 polyunsaturated rich diet (Mata et al, 1997) . In addition to the difference in supplementation regimes between the current study and that of Mata et al, (1997) , the other major difference between the two studies was in the origin of the cell line used to assess growth factor activity. Although both studies employed arterial smooth muscle cells, the current study used umbilical arterial smooth muscle cells while the earlier one used coronary smooth muscle cells.
Fish oil has previously been reported to reduce the occurrence of early restenosis after coronary angioplasty in men (Dehmer et al, 1988) . In vitro studies have reported that the two major n-3 fatty acids present in ®sh, EPA and DHA reduce smooth muscle cell proliferation (Pakala et al, 1999) . Inhibition of cell proliferation, together with other well-documented effects of ®sh oil decreasing platelet aggregation (Mori et al., 1997) , blood pressure (Morris et al, 1993) and modulating blood lipids (Connor et al, 1993) , may contribute to the reported reduction in restenosis. Given that growth factor activity is higher following angioplasty (Caplice et al, 1997) , it is possible that ®sh oil exerts lowering effects only in pathological states where growth factor levels are elevated. This may explain our observation of no signi®cant effect of ®sh oil on serum growth factor activity in apparently healthy individuals.
In summary, our results demonstrate the low-dose ®sh oil supplementation, at levels achievable by increasing dietary fatty ®sh intakes, over an 8 week intervention, at levels alter the total growth factor activity of serum or modify serum concentrations of TGFb or PDGF in apparently healthy individuals. Whether ®sh oil would have a positive effect on growth factor activity in patients at risk of vascular disease, and previously reported to have increased growth factor levels, remains to be elucidated.
